Study of changes in intestinal motility and microbiota during the correction of experimental dysbiosis by autoprobiotic and probiotic Escherichia

The effect of probiotic and autoprobiotic (indigenous non-pathogenic) E. coli on intestinal motility and microbiota in experimental intestinal dysbiosis in male Wistar rats was studied. The administration of ampicillin and metronidazole led to a decrease in appetite, weight loss, and diarrhea. In animals with intestinal dysbiosis, there was a decrease in the amplitude of intestinal wall contractions and the amount of work performed by the smooth muscle cells of the intestinal wall, compared to the control group of intact animals (K2), accompanied by an increase in the population of Klebsiella and Bacteroides fragilis group. In contrast to the control group K1, which did not receive any treatment for dysbiosis, the administration of probiotic and autoprobiotic E. coli resulted in a decrease in the number of opportunistic pathogens and an increase in the number of fecalibacteria (butyrate producers). Changes in the microbiota contributed to the restoration of motor activity in the distal colon of rats.

Klebsiella dysbiosis, amplitudes and frequency of intestinal wall contractions, smooth muscle cells, Bacteroides fragilis group, Faecalibacterium prausnitzii

1. Ma T., Shen X., Shi X. et al. Targeting gut microbiota and metabolism as the major probiotic mechanism - An evidence-based review. Trends in Food Science & Technology. 2023. doi: 10.1016/j.tifs.2023.06.013.

2. Frese S.A., Hutkins R.W., Walter J.Comparison of the colonization ability of autochthonous and allochthonous strains of lactobacilli in the human gastrointestinal tract. Advances in Microbiology. 2012; 2 (03): 399. doi: 10.4236/aim.2012.23051.

3. Jones M.L., Tomaro-Duchesneau C., Martoni C.J., Prakash S. Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications/ Expert opinion on biological therapy. 2013; 13(5): 631-642. doi: 10.1517/14712598.2013.758706.

4. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nature reviews Gastroenterology & hepatology. 2010; 7(9): 503-514. doi: 10.1038/nrgastro.2010.117.

5. Ermolenko E.I., Erofeev N.P., Zakharova L.B. et al. Features of the composition of intestinal microbiota and motility after correction of experimental dysbiosis with probiotic and autoprobiotic enterococci. Experimental and Clinical Gastroenterology. 2017; 7(143). (In Russ.)@@ Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б., Парийская Е.Н., Котылева М.П., Крамская Т.А., Карасева А.Б., Суворов А.Н. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017; 7(143).

6. Ermolenko E.I. Lactic acid bacteria. 2011. LAP Lambert Academic Publishing GmbH & Co. KG. 283 P. (In Russ.)@@ Ермоленко Е.И. Молочнокислые бактерии. 2011 LAP Lambert Academic Publishing GmbH & Co. KG. 283 с.

7. Baryshnikova N., Ermolenko E., Svarval A. et al. Enterococcus faecium L-3 in eradication of Helicobacter pylori: in-vivo and in-vitro.International Journal of Clinical & Medical Microbiology. 2017; 2:123-127. doi: 10.15344/2456-4028/2017/123.

8. Suvorov A.N., Simanenkov V.I., Sundukova Z.R. et al. Method for producing an autoprobiotic based on Enterocuccus faecium, a representative of the indigenous microflora of the host intestine. Patent for invention RUS 2460778, December 30, 2010. (In Russ.)@@ Суворов А.Н., Симаненков В.И., Сундукова З.Р. и др. Способ получения аутопробиотика на основе Enterocuccus faecium, представителя индигенной микрофлоры кишечника хозяина. Патент на изобретение RUS 2460778 30.12.2010.

9. Ermolenko E.I., Zhdan-Pushkina S. Kh., Suvorov A.N.Interaction of Candida albicans and Lactobacillus plantarum in vitro. Problems of Medical Mycology. 2004; 6(2): 49-54. (In Russ.)@@ Ермоленко Е.И., Ждан-Пушкина С.Х., Суворов А.Н. Взаимодействие Candida albicans и Lactobacillus plantarum in vitro. Проблемы медицинской микологии. 2004; 6(2): 49-54.

10. Kapustina V.V., Zakharova L.B., Pariyskaya E.N. et al. Effect of probiotics on the microbiota and morphofunctional characteristics of the intestine in experimental dysbiosis. Problems of Medical Mycology. 2020; 22 (3): 83. (In Russ.)@@ Капустина В.В., Захарова Л.Б., Парийская Е.Н. и др. Влияние пробиотиков на микробиоту и морфофункциональные характеристики кишечника при экспериментальном дисбиозе. Проблемы медицинской микологии. 2020; 22 (3): 83.

11. Milyukhina I.V., Ermolenko E.I., Ivanova A.S., Suvorov A.N. The role of the gastrointestinal tract microbiota in the pathogenesis of Parkinson’s disease. Neurological journal. 2017; 22(6): 280-286. (In Russ.)@@ Милюхина И.В., Ермоленко Е.И., Иванова А.С., Суворов, А.Н. Роль микробиоты желудочно-кишечного тракта в патогенезе болезни Паркинсона. Неврологический журнал. 2017; 22(6): 280-286.

12. Simanenkov V.I., Suvorov A.N., Solovieva O.I. et al. A method for producing a personalized autoprobiotic product and a method for treating irritable bowel syndrome using this product. Patent for invention RUS 2546253, April 25, 2013 (In Russ.)@@ Симаненков В.И., Суворов А.Н., Соловьева О.И. и др. Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженной кишки с использованием этого продукта. Патент на изобретение RUS 2546253 25.04.2013.

13. Suvorov A.N., Ermolenko E.I., Kotyleva M.P., Tsapieva A.N. Application No. 2018 147697 dated December 28, 2018 (536 according to the IEM register): Method for preparing an autoprobiotic based on an anaerobic bacterial consortium. Positive decision on issuing a patent dated June 23, 2020. (In Russ.)@@ Суворов А.Н., Ермоленко Е.И., Котылева М.П., Цапиева А.Н. Заявка № 2018 147697 от 28.12.2018 (536 по реестру ИЭМ): Способ приготовления аутопробиотика на основе анаэробного консорциума бактерий. Положительное решение о выдаче патента от 23.06.2020.

14. Fukuda S., Ohno H. Gut microbiome and metabolic diseases. Seminars in immunopathology. Berlin/Heidelberg: Springer Berlin Heidelberg. 2014; 36 (1): 103-114. doi: 10.1007/s00281-013-0399-z.

15. Ermolenko E.I., Donets V.N., Dmitrieva Y.V. et al. Influence of probiotic enterococci on functional characteristics of rat bowel under dysbiosis induced by antibiotics. Bulletin of St. Petersburg State University. 2009; 1: 157-167.

16. Tarasova E., Ermolenko E., Donets V. et al. The influence of probiotic Enterococcus faecium strain L5 on the microbiota and cytokines expression in rats with dysbiosis induced by antibiotics. Beneficial microbes. 2010;.1(3): 265-270.

17. Jean S., Wallace M.J., Dantas G. et al. Burnham CD. Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group. J Clin Microbiol. 2022; 60: e0236120. doi: 10.1128/jcm.02361-20.

18. Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Frontiers in microbiology. 2018; 9: 1869. https://doi.org/10.3389/fmicb.2018.01869.

19. Teplova A.S., Demidova T. Yu., Korotkova T.N. Butyric acid and its prospects in obesity management. Experimental and Clinical Gastroenterology. 2023; 10(218): 88-94. (In Russ.) doi: 10.31146/1682-8658-ecg-218-10-88-94.@@ Теплова А.С., Демидова Т.Ю., Короткова Т.Н. Масляная кислота и её перспективы в управлении ожирением. Экспериментальная и клиническая гастроэнтерология. 2023; 10(218): 88-94. doi: 10.31146/1682-8658-ecg-218-10-88-94.

20. Erofeev N.P., Seliverstov P.V., Radchenko V.G. Clinical physiology of the colon. Mechanisms of action of short-chain fatty acids in normal and pathological conditions. Moscow. «4TE ART» LLC. 2012. (In Russ.)@@ Ерофеев Н.П., Селиверстов П.В., Радченко В.Г. Клиническая физиология толстой кишки. Механизмы действия короткоцепочечных жирных кислот в норме и при патологии. М.: ООО «4ТЕ АРТ», 2012. 56 с.

21. Ermolenko E.I., Zakharova L.B., Pariyskaya E.N. Potential influence of endotoxin and butyric acid on contractile activity of the colon in experimental dysbiosis. Health is the basis of human potential: problems and solutions. 2018; 1012-1024. (In Russ.)@@ Ермоленко Е.И., Захарова Л.Б., Парийская Е.Н. Потенциальное влияние эндотоксина и масляной кислоты на сократительную активность толстой кишки при экспериментальном дисбиозе. Здоровье-основа человеческого потенциала: проблемы и пути их решения. 2018; 1012-1024.

22. Ermolenko E.I., Erofeev N.P., Zakharova L.B. et al. Features of the composition of intestinal microbiota and motility after correction of experimental dysbiosis with probiotic and autoprobiotic enterococci. Experimental and Clinical Gastroenterology. 2017; 7: 143. (In Russ.)@@ Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б. и др. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017; 7: 143.

23. Ivanov A.A., Troshina I.A., Golubeva T.I. et al. Short-chain fatty acids: metabolism, functions, and diagnostic potential in metabolic disorders. Perm Medical Journal. 2024; 41(6): 109-119. (In Russ.) doi: 10.17816/pmj416109-119.@@ Иванов А.А., Трошина И.А., Голубева Т.И. и др. Короткоцепочечные жирные кислоты: метаболизм, функции и диагностический потенциал при метаболических нарушениях. Пермский медицинский журнал. 2024; 41(6): 109-119. doi: 10.17816/pmj416109-119.

24. Vicentini F., Keenan C., Wallace L. et al.Intestinal microbiota shapes gut physiology and regulates enteric neurons and glia. Microbiome. 2021; 9: 210. doi: 10.1186/s40168-021-01165-z.

25. Wang L., Lv W-Q., Yang J-T., et al. Enteric nervous system damage caused by abnormal intestinal butyrate metabolism may lead to functional constipation. Front. Microbiol. 2023; 14: 1117905. doi: 10.3389/fmicb.2023.1117905.